SLDB Solid Biosciences Inc

Solid Biosciences to Present at Upcoming Investor Conferences

Solid Biosciences to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Joel Schneider, PhD, Chief Technology Officer, and Cathryn Clary, MD, MBA, Acting Chief Medical Officer, will participate at the following two upcoming investor conferences:

  • SVB Leerink 10th Annual Global Healthcare Conference

    Fireside chat on Wednesday, February 24, 2021 at 1:40 p.m. ET.
  • Barclays Global Healthcare Conference

    Fireside chat on Thursday, March 11, 2021 at 9:45 a.m. ET.

A live webcast of these presentations will be available on the Company’s investor relations website, under the Events page accessible here: . A replay will be available on the Company's website following the event.

About Solid Biosciences

Solid Biosciences is a life sciences company focused on advancing transformative treatments to improve the lives of patients living with Duchenne. Disease-focused and founded by a family directly impacted by Duchenne, our mandate is simple yet comprehensive – work to address the disease at its core by correcting the underlying mutation that causes Duchenne with our lead gene therapy candidate, SGT-001. For more information, please visit .

Investor Contact:

David Carey

FINN Partners

212-867-1768

Media Contact:

Erich Sandoval

FINN Partners

917-497-2867



EN
17/02/2021

Underlying

SLDBSolid Biosciences Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Solid Biosciences Inc

 PRESS RELEASE
Free
SLDB Solid Bioscienc...

Solid Biosciences Receives FDA Fast Track Designation for SGT-501 Firs...

Solid Biosciences Receives FDA Fast Track Designation for SGT-501 First-in-Class Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) - SGT-501 has now received FDA Fast Track, Orphan Drug and Rare Pediatric Disease designations - - Potential first-in-class therapy with FDA IND clearance and Health Canada CTA approval designed to address underlying causes of CPVT, a life-threatening, arrhythmogenic cardiac condition - - Solid expects to initiate Phase 1b clinical trial of SGT-501 in the fourth quarter of 2025 - CHARLESTOWN, Mass., July 23, 2025 (GLOBE NEWSW...

July 23, 2025 1 EN
 PRESS RELEASE
Free
SLDB Solid Bioscienc...

Solid Biosciences Announces FDA IND and Health Canada CTA Approval for...

Solid Biosciences Announces FDA IND and Health Canada CTA Approval for First-in-Class Cardiac Gene Therapy to Treat Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) - SGT-501 is a novel gene therapy for rare, life-threatening, genetic arrhythmogenic disease with no approved therapies - - SGT-501 has received Orphan Drug Designation and Rare Pediatric Disease Designation from the FDA - - Solid expects to initiate Phase 1b clinical trial of SGT-501 in the fourth quarter of 2025 - - Expands Solid’s clinical pipeline to include first cardiac indication with urgent unmet medical n...

July 8, 2025 1 EN
 PRESS RELEASE
Free
SLDB Solid Bioscienc...

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule ...

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CHARLESTOWN, Mass., July 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 105,330 restricted stock units (“RSUs”) to seven newly hired employees. The RSUs vest in four equal installments on each one-year anniversary of the grant date until the fourth anniversary of the grant date. Vesting of the equity awards is subject to the applicable employee’...

July 1, 2025 1 EN
 PRESS RELEASE
Free
SLDB Solid Bioscienc...

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule ...

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CHARLESTOWN, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 34,550 restricted stock units (“RSUs”) to two newly hired employees. The RSUs vest in four equal installments on each one-year anniversary of the grant date until the fourth anniversary of the grant date. Vesting of the equity awards is subject to the applicable employee’s c...

June 3, 2025 1 EN
 PRESS RELEASE
Free
SLDB Solid Bioscienc...

Solid Biosciences to Participate at the Jefferies Global Healthcare Co...

Solid Biosciences to Participate at the Jefferies Global Healthcare Conference CHARLESTOWN, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, announced that Bo Cumbo, President and CEO, and Gabriel Brooks, M.D., Chief Medical Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 4, at 2:00 pm ET. A live webcast of the fireside chat will be available on the Events page of the I...

May 28, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch